HSK-III-001

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHSK-III-001
Drug Alias NameHSK-III-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesHaisco Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLiaoning Haisco Pharmaceutical Co LtdSichuan Haisco Pharmaceutical Co LtdHaisco Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A